Journals / The Anatolian Journal of Cardiology / 2017 / Cilt: 17 - Sayı: 2

Low acylation stimulating protein levels are associated with cardiometabolic disorders–secondary to autoimmune activation?

Pages
97–106
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In women, incident CHD was predicted by either reduced or elevated ASP tertiles.Conclusion: Findings can be explained by the notion of operation of immune responses against both ASP and oxidized PAF-like lipids of Lp(a) to yield for “reduced” values and increased likelihood of cardiometabolic disorders

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: We investigated the possible association of serum acylation stimulating protein (ASP) with cardiometabolic disorders and the evidence of autoimmune activation.Methods: Population-based randomly selected 1024 participants were cross-sectionally and prospectively analyzed.
📊
Key Findings & Data:Correlations were sought separately in subjects with no cardiometabolic disorders (n=427) designated as “healthy.”Results: ASP was positively correlated with total testosterone and inversely correlated with platelet activating factor (PAF), PAF-acetylhydrolase (AH), in each gender, and positively correlated in “healthy” men with lipoprotein [Lp](a) and apolipoprotein B.
💡
Conclusion & Impact:In women, incident CHD was predicted by either reduced or elevated ASP tertiles.Conclusion: Findings can be explained by the notion of operation of immune responses against both ASP and oxidized PAF-like lipids of Lp(a) to yield for “reduced” values and increased likelihood of cardiometabolic disorders
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: We investigated the possible association of serum acylation stimulating protein (ASP) with cardiometabolic disorders and the evidence of autoimmune activation.Methods: Population-based randomly selected 1024 participants were cross-sectionally and prospectively analyzed. ASP concentrations were measured with a validated ELISA kit. Correlations were sought separately in subjects with no cardiometabolic disorders (n=427) designated as “healthy.”Results: ASP was positively correlated with total testosterone and inversely correlated with platelet activating factor (PAF), PAF-acetylhydrolase (AH), in each gender, and positively correlated in “healthy” men with lipoprotein [Lp](a) and apolipoprotein B. Correlations of ASP with PAF values ≥22 nmol/L were abolished, contrasted to a strongly inverse one in subjects with PAF <22 nmol/L. In linear regression analyses in the whole sample, ASP was inversely associated independently with PAF and PAF-AH and, in men, positively with Lp(a) and sex hormone-binding globulin. Prevalent and (at 2.0 years’ follow-up) incident metabolic syndrome (MetS, n=393), diabetes (n=154), and coronary heart disease (CHD, n=171) were analyzed by sex-, age-, and Lp(a)-adjusted logistic regression, using tertiles of ASP and PAF. The lower two (<42 nmol/L) ASP tertiles were a risk factor in combined sexes for MetS and diabetes. In women, incident CHD was predicted by either reduced or elevated ASP tertiles.Conclusion: Findings can be explained by the notion of operation of immune responses against both ASP and oxidized PAF-like lipids of Lp(a) to yield for “reduced” values and increased likelihood of cardiometabolic disorders

🔖

Cite This Article

ONAT, A., ALTAY, S., YÜKSEL, M., KARADENİZ, Y., CAN, G., YÜKSEL, H., ADEMOĞLU, E. (2017). Low acylation stimulating protein levels are associated with cardiometabolic disorders–secondary to autoimmune activation?. The Anatolian Journal of Cardiology, Cilt: 17 - Sayı: 2, 97–106. https://ajindex.com/articles/366700

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Cianflone K, Xia Z, Chen LY. Critical review of acylation-stimulating protein physiology in humans and rodents. Biochim Biophys Acta 2003
  2. 43 2. Onat A, Can G, Rezvani R, Cianflone K. Complement C3 and cleavage products in cardiometabolic risk. Clin Chim Acta 2011
  3. 9 3. Maslowska M, Vu H, Phelis S, Sniderman AD, Rhode BM, Blank D, et al. Plasma acylation stimulating protein, adipsin and lipids in non-obese and obese populations. Eur J Clin Invest 1999
  4. 86 4. Weyer C, Pratley RE. Fasting and postprandial plasma concentrations of acylation-stimulation protein (ASP) in lean and obese Pima Indians compared to Caucasians. Obes Res 1999
  5. Yeşilova Z, Özata M, Öktenli C, Bağcı S, Özcan A, Sanisoğlu SY, et al. Increased acylation stimulating protein concentrations in nonalcoholic fatty liver disease are associated with insulin resistance. Am J Gastroenterol 2005
  6. Özata M, Güngör D, Turan M, Özışık G, Bingöl N, Özgürtaş T, et al. Improved glycemic control increases fasting plasma acylationstimulating protein and decreases leptin concentrations in type II diabetic subjects. J Clin Endocrinol Metab 2001
  7. Yang Y, Lu HL, Zhang J, Yu HY, Wang HW, Zhang MX, et al. Relationships among acylation stimulating protein, adiponectin and complement C3 in lean vs. obese type 2 diabetes. Int J Obesity 2006
  8. Wu Y, Zhang J, Wen Y, Wang H, Zhang M, Cianflone K. Increased acylation-stimulating protein, C-reactive protein, and lipid levels in young women with polycystic ovary syndrome. Fertil Steril 2009
  9. Tang JH, Wen Y, Wu F, Zhao XY, Zhang MX, Mi J, et al. Increased plasma acylation-stimulating protein in pediatric proteinuric renal disease. Pediatric Nephrology 2008
  10. St-Pierre DH, Cianflone K, Smith J, Coderre L, Karelis AD, Imbeault P, et al. Change in plasma acylation stimulating protein during euglycaemic-hyperinsulinaemic clamp in overweight and obese postmenopausal women: a MONET study. Clin Endocrinol 2009
  11. Castro-Faria-Neto HC, Stafforini DM, Prescott SM, Zimmerman GA. Regulating inflammation through the anti-inflammatory enzyme platelet-activating factor-acetyl hydrolase. Mem Inst Oswaldo Cruz 2005
  12. 100(Suppl 1): 83-91. 12. Marathe GK, Zimmerman GA, Prescott SM, McIntyre TM. Activation of vascular cells by PAF-like lipids in oxidized LDL. Vascul Pharmacol 2002
  13. Prescott SM, Zimmerman GA, Stafforini DM, McIntyre TM. Platelet-